Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Sharon L Mount & Gamal H Eltabbakh. (2001) Tamoxifen and the female reproductive tract. Expert Opinion on Pharmacotherapy 2:9, pages 1399-1413.
Read now
Read now
J. M. Elias, A. Heimann, T. Cain, M. Margiotta, F. Gallery & C. Gomes. (1990) Estrogen Receptor Localization in Paraffin Sections By Enzyme Digestion, Repeated Applications of Primary Antibody, and Imidazole. Journal of Histotechnology 13:1, pages 29-33.
Read now
Read now
V. Craig Jordan. (1988) Chemosuppression of Breast Cancer with Tamoxifen: Laboratory Evidence and Future Clinical Investigations. Cancer Investigation 6:5, pages 589-595.
Read now
Read now
Articles from other publishers (40)
V. Craig Jordan. 2022. Tamoxifen Tales. Tamoxifen Tales
83
104
.
Ping Fan, Philipp Y. Maximov, Ramona F. Curpan, Balkees Abderrahman & V. Craig Jordan. (2015) The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy. Molecular and Cellular Endocrinology 418, pages 245-263.
Crossref
Crossref
V Craig Jordan. (2015) The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. Endocrine-Related Cancer 22:1, pages R1-R31.
Crossref
Crossref
MEI HONG ZHANG, HONG TAO MAN, XIAO DAN ZHAO, NI DONG & SHI LIANG MA. (2014) Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review). Biomedical Reports 2:1, pages 41-52.
Crossref
Crossref
Russell E. McDaniel, Philipp Y. Maximov & V. Craig Jordan. 2013. Hormones and Breast Cancer. Hormones and Breast Cancer
1
49
.
Alejandro Ariel Gru & Donald Craig Allred. 2013. Molecular Surgical Pathology. Molecular Surgical Pathology
95
128
.
Mingli Liu, Guangdi Wang, Carmen R. Gomez-Fernandez & Shanchun Guo. (2012) GREB1 Functions as a Growth Promoter and Is Modulated by IL6/STAT3 in Breast Cancer. PLoS ONE 7:10, pages e46410.
Crossref
Crossref
Julie A. Guidroz & Ronald J. Weigel. 2011. Breast Surgical Techniques and Interdisciplinary Management. Breast Surgical Techniques and Interdisciplinary Management
83
96
.
Sandy H. Fang, Yizhen Chen & Ronald J. Weigel. (2009) GATA-3 as a Marker of Hormone Response in Breast Cancer. Journal of Surgical Research 157:2, pages 290-295.
Crossref
Crossref
Geeta Lal, Samad Hashimi, Brian J. Smith, Charles F. Lynch, Lurong Zhang, Robert A. Robinson & Ronald J. Weigel. (2009) Extracellular Matrix 1 (ECM1) Expression Is a Novel Prognostic Marker for Poor Long-Term Survival in Breast Cancer: A Hospital-Based Cohort Study in Iowa. Annals of Surgical Oncology 16:8, pages 2280-2287.
Crossref
Crossref
Andr? Albergaria, Joana Paredes, B?rbara Sousa, Fernanda Milanezi, V?tor Carneiro, Joana Bastos, Sandra Costa, Daniella Vieira, Nair Lopes, Eric W Lam, Nuno Lunet & Fernando Schmitt. (2009) Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours. Breast Cancer Research 11:3.
Crossref
Crossref
George W. Woodfield, Michael J. Hitchler, Yizhen Chen, Frederick E. Domann & Ronald J. Weigel. (2009) Interaction of TFAP2C with the Estrogen Receptor-α Promoter Is Controlled by Chromatin Structure. Clinical Cancer Research 15:11, pages 3672-3679.
Crossref
Crossref
Anamaria Ioan, Merieme Klobocista, Sherin Shirazi & Michael F. Press. 2009. The Breast. The Breast
501
531
.
George W. Woodfield, Annamarie D. Horan, Yizhen Chen & Ronald J. Weigel. (2007) TFAP2C Controls Hormone Response in Breast Cancer Cells through Multiple Pathways of Estrogen Signaling. Cancer Research 67:18, pages 8439-8443.
Crossref
Crossref
Rigen Mo, Yiwei Tony Zhu, Zhongyi Zhang, Sambasiva M. Rao & Yi-Jun Zhu. (2007) GAS6 is an estrogen-inducible gene in mammary epithelial cells. Biochemical and Biophysical Research Communications 353:1, pages 189-194.
Crossref
Crossref
V.C. Jordan. 2007. Comprehensive Medicinal Chemistry II. Comprehensive Medicinal Chemistry II
83
102
.
Paul R. Stabach, Manimekalai M. Thiyagarajan & Ronald J. Weigel. (2005) Expression of ZER6 in ERα-Positive Breast Cancer. Journal of Surgical Research 126:1, pages 86-91.
Crossref
Crossref
Purvi Parikh, Juan P. Palazzo, Lewis J. Rose, Constantine Daskalakis & Ronald J. Weigel. (2005) GATA-3 Expression as a Predictor of Hormone Response in Breast Cancer. Journal of the American College of Surgeons 200:5, pages 705-710.
Crossref
Crossref
Yuzhi Jia, Chao Qi, Zhongyi Zhang, Yiwei Tony Zhu, Sambasiva M. Rao & Yi-Jun Zhu. (2005) Peroxisome Proliferator-activated Receptor-binding Protein Null Mutation Results in Defective Mammary Gland Development. Journal of Biological Chemistry 280:11, pages 10766-10773.
Crossref
Crossref
Margaret A Shupnik. (2004) Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation. Oncogene 23:48, pages 7979-7989.
Crossref
Crossref
P T K Saunders, M R Millar, K Williams, S Macpherson, C Bayne, C O'Sullivan, T J Anderson, N P Groome & W R Miller. (2002) Expression of oestrogen receptor beta (ERβ1) protein in human breast cancer biopsies. British Journal of Cancer 86:2, pages 250-256.
Crossref
Crossref
Eric R. Schuur, Lisa A. McPherson, George P. Yang & Ronald J. Weigel. (2001) Genomic Structure of the Promoters of the Human Estrogen Receptor-α Gene Demonstrate Changes in Chromatin Structure Induced by AP2γ. Journal of Biological Chemistry 276:18, pages 15519-15526.
Crossref
Crossref
Renee V. Hoch, Devon A. Thompson, Robin J. Baker & Ronald J. Weigel. (1999) GATA-3 is expressed in association with estrogen receptor in breast cancer. International Journal of Cancer 84:2, pages 122-128.
Crossref
Crossref
Charles Carmeci, Devon A. Thompson, Wayne W. Kuang, Nina Lightdale, Heinz Furthmayr & Ronald J. Weigel. (1998) Moesin expression is associated with the estrogen receptor–negative breast cancer phenotype. Surgery 124:2, pages 211-217.
Crossref
Crossref
V.Craig Jordan & William J. Gradishar. (1997) Molecular mechanisms and future uses of antiestrogens. Molecular Aspects of Medicine 18:3, pages 167-247.
Crossref
Crossref
W.R. Miller & S.P. Langdon. (1997) Steroid hormones and cancer: (III) Observations from human subjects. European Journal of Surgical Oncology (EJSO) 23:2, pages 163-177.
Crossref
Crossref
W.R. Miller & S.P. Langdon. (1997) Steroid hormones and cancer: (II) lessons from experimental system. European Journal of Surgical Oncology (EJSO) 23:1, pages 72-83.
Crossref
Crossref
W.R. Miller. (1996) Steroid hormones and cancer: (I) Basic biology and endocrinology. European Journal of Surgical Oncology (EJSO) 22:6, pages 627-633.
Crossref
Crossref
Edward E. Wallach, Yair Daniel, Moshe Inbar, Amiram Bar-Am, M. Reuben Peyser & Joseph B. Lessing. (1996) The effects of tamoxifen treatment on the endometrium. Fertility and Sterility 65:6, pages 1083-1089.
Crossref
Crossref
Debra A. Tonetti & V. Craig Jordan. (1996) Targeted anti-estrogens to treat and prevent diseases in women. Molecular Medicine Today 2:5, pages 218-223.
Crossref
Crossref
Suzanne A. W. Fuqua & Douglas M. Wolf. (1995) Molecular aspects of estrogen receptor variants in breast cancer. Breast Cancer Research and Treatment 35:3, pages 233-241.
Crossref
Crossref
Douglas M. Wolf & V. Craig Jordan. (1994) Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice. Breast Cancer Research and Treatment 31:1, pages 117-127.
Crossref
Crossref
Andreas Friedl, V. Craig Jordan & Michael Pollak. (1993) Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy. European Journal of Cancer 29:10, pages 1368-1372.
Crossref
Crossref
Douglas M. Wolf & V. Craig Jordan. (1993) Drug resistance to tamoxifen during breast cancer therapy. Breast Cancer Research and Treatment 27:1-2, pages 27-40.
Crossref
Crossref
David FC Gibson, Delinda A. Johnson, Susan M. Langan-Fahey, Mary K. Lababidi, William H. Wolberg & V. Craig Jordan. (1993) The effects of intermittent progesterone upon tamoxifen inhibition of tumor growth in the 7,12-dimethylbenzanthracene rat mammary tumor model. Breast Cancer Research and Treatment 27:3, pages 283-287.
Crossref
Crossref
D. M. Wolf & V. C. Jordan. 1993. Adjuvant Therapy of Breast Cancer IV. Adjuvant Therapy of Breast Cancer IV
23
33
.
Shun-yuan Jiang, Douglas M. Wolf, Jonathan M. Yingling, Chawnshang Chang & V.Craig Jordan. (1992) An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol. Molecular and Cellular Endocrinology 90:1, pages 77-86.
Crossref
Crossref
Douglas M. Wolf & V.Craig Jordan. (1992) Gynecologic complications associated with long-term adjuvant tamoxifen therapy for breast cancer. Gynecologic Oncology 45:2, pages 118-128.
Crossref
Crossref
David N. DanforthJr.Jr.. (1992) Hormone receptors in malignancy. Critical Reviews in Oncology/Hematology 12:2, pages 91-149.
Crossref
Crossref
R.W. Koot, G.J. Amelink, M.A. Blankenstein & P.R. Bär. (1991) Tamoxifen and oestrogen both protect the rat muscle against physiological damage. The Journal of Steroid Biochemistry and Molecular Biology 40:4-6, pages 689-IN10.
Crossref
Crossref